HOUSTON – November 14, 2026 -- Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ) has launched 4RISE, a high-throughput wet-lab validation service for AI-designed protein binders, with sequence-to-data turnaround of as little as 3 days. Protein expression accounts for 3 of those 72 hours, about 4% by our calculation, so the other roughly 69 hours cover the steps after expression, including binding screening and analysis.
Cell-free platform expresses six protein formats in 3 hours
The expression step runs on Sino Biological's XPressMAX cell-free protein synthesis platform. The company says expression success rates exceed 99% in established workflows, which implies fewer than 1 in 100 expressions fail in those workflows. The platform handles miniproteins, VHHs, scFvs, Fabs, enzymes and cytokines.
4RISE screens binders on three instrument platforms and four service lines
Binding screening, kinetic analysis and affinity determination run on Carterra high-throughput SPR, Biacore SPR and Octet BLI instruments. Customers can retrieve structured binding data in real time through an API.
The service is sold in four workflows:
- Rapid Hit Discovery: crude-supernatant screening that identifies binding-positive miniproteins and VHHs.
- Comparative Binder Screening: purified candidates tested under standardized conditions to support prioritization.
- Affinity & Kinetic Characterization: quantitative binding data for lead selection.
- Specialized Binder Expression & Validation: tailored mammalian expression and binding analysis for other binder formats.
Beyond binding, Sino Biological lists 20+ developability assays, 1,000+ protein bioactivity assays and 10+ cell-based functional assays. That is at least 1,030 assays by our calculation.
AI drug-discovery teams get binding data without building their own wet lab
The offer targets companies that design binders computationally and need experimental confirmation of target binding. Sino Biological says it already works with AI companies on AI-designed antibody discovery, de novo binder design and computational protein engineering. API delivery lets those teams feed results into downstream analysis directly.
"AI-designed molecules need reliable wet-lab experimental evidence to demonstrate their potential," said Dr. Rob Burgess, Chief Business Officer at Sino Biological US. He said the integrated capabilities help researchers evaluate candidates quickly and shorten design cycles.
The company did not disclose pricing or capacity for the service.
Sino Biological says 4RISE wet-lab validation has supported studies published in Science, Nature Communications and Scientific Reports.